a method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved efficacy over conventional warfarin therapy.
- 专利权人:
- Boehringer Ingelheim International GMBH
- 发明人:
- Paul A. Reilly
- 申请号：
- BRPI0921354
- 公开号：
- BRPI0921354A2
- 申请日:
- 2009.11.10
- 申请国别(地区):
- BR
- 年份:
- 2019
- 代理人:
- 摘要：
- A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- A method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved efficacy over conventional warfarin therapy.
- Method for treating or preventing thrombosis using dabigatran etexylate or a salt thereof with improved safety profile compared to conventional warfarin therapy
- METHOD FOR TREATING OR PREVENTING THROMBOSIS USING >；150 MG TO 300 MG B.I.D. OF DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
- METHOD FOR TREATING OR PREVENTING THROMBOSIS USING 150 MG B.I.D. OF DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
- METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
